摘要:
A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of phenyl derivatives of imidazolone compounds of Formula I. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
摘要:
A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of heteroaryl derivatives of imidazolone compounds of Formula 1. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
摘要:
A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of acyclic derivatives of imidazolone compounds of Formula I. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
摘要:
The present invention provides novel prodrug derivatives of fluorooxindoles having the general Formula I wherein the wavy bond () represents the racemate, the (R)-enantiomer or the (S)-enantiomer, and R1, R2, R3, R4 and X are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.
摘要翻译:本发明提供具有通式I的氟氧吲哚的新型前药衍生物,其中波状键(<?img id =“CUSTOM-CHARACTER-00001”he =“2.46mm”wi =“4.23mm”file =“US06916937-20050712- 代表外消旋物,(R) - 对映异构体或(S) - 对映异构体,而R(R) - 对映异构体或(S) R 1,R 2,R 3,R 4和X如本文所定义,或无毒的药学上可接受的盐或溶剂化物 并且可用于治疗对钾通道开放有反应的病症。
摘要:
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
摘要:
The invention encompasses compounds of Formula I, which are blockers of KCNQ channels. Blockers of KCNQ channels are known to enchance cognition in laboratory animals. The invention includes, salts, solvates, compositions, and methods of use.